Arcturus Therapeutics Holdings Inc.
ARCT
$12.91
$0.020.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -26.22% | -7.68% | 373.99% | -52.65% | -80.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.22% | -7.68% | 373.99% | -52.65% | -80.75% |
| Cost of Revenue | 19.55% | -23.38% | 17.03% | 1.94% | 35.73% |
| Gross Profit | -264.51% | 142.77% | 571.01% | -151.76% | -104.32% |
| SG&A Expenses | -1.02% | -0.76% | -6.87% | 7.91% | 5.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.32% | -18.69% | 7.73% | 3.20% | 26.48% |
| Operating Income | -82.76% | 44.41% | 61.85% | -300.69% | -115.04% |
| Income Before Tax | -162.20% | 53.55% | 66.59% | -152.01% | -109.65% |
| Income Tax Expenses | -101.53% | -124.30% | -126.00% | 257.28% | -79.77% |
| Earnings from Continuing Operations | -156.30% | 57.45% | 67.24% | -152.84% | -109.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -156.30% | 57.45% | 67.24% | -152.84% | -109.98% |
| EBIT | -82.76% | 44.41% | 61.85% | -300.69% | -115.04% |
| EBITDA | -86.60% | 46.85% | 63.00% | -287.23% | -114.31% |
| EPS Basic | -152.80% | 58.21% | 67.73% | -152.20% | -109.93% |
| Normalized Basic EPS | -158.64% | 54.40% | 67.09% | -249.89% | -109.60% |
| EPS Diluted | -151.18% | 58.21% | 67.73% | -153.48% | -110.22% |
| Normalized Diluted EPS | -158.64% | 54.40% | 67.09% | -253.28% | -109.81% |
| Average Basic Shares Outstanding | 1.40% | 1.84% | 1.52% | 1.22% | 0.45% |
| Average Diluted Shares Outstanding | 1.40% | 1.84% | 1.52% | -0.99% | -1.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |